The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance

The current treatment options for type 2 diabetes mellitus do not adequately control the disease in many patients. Consequently, there is a need for new drugs to prevent and treat type 2 diabetes mellitus. Among the new potential pharmacological strategies, activators of peroxisome proliferator-acti...

ver descrição completa

Detalhes bibliográficos
Autores: Aguilar-Recarte, David, Palomer Tarridas, Francesc Xavier, Wahli, Walter, Vázquez Carrera, Manuel
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/183848
Acesso em linha:https://hdl.handle.net/2445/183848
Access Level:acceso abierto
Palavra-chave:Trastorns del metabolisme dels lípids
Àcids grassos
Receptors nuclears (Bioquímica)
Glucosa
Lipid metabolism disorders
Fatty acids
Nuclear receptors (Biochemistry)
Glucose
id ES_ca4c72fba5953e5bddd8b45046bb803f
oai_identifier_str oai:recercat.cat:2445/183848
network_acronym_str ES
network_name_str España
repository_id_str
spelling The PPARβ/δ-AMPK Connection in the Treatment of Insulin ResistanceAguilar-Recarte, DavidPalomer Tarridas, Francesc XavierWahli, WalterVázquez Carrera, ManuelTrastorns del metabolisme dels lípidsÀcids grassosReceptors nuclears (Bioquímica)GlucosaLipid metabolism disordersFatty acidsNuclear receptors (Biochemistry)GlucoseThe current treatment options for type 2 diabetes mellitus do not adequately control the disease in many patients. Consequently, there is a need for new drugs to prevent and treat type 2 diabetes mellitus. Among the new potential pharmacological strategies, activators of peroxisome proliferator-activated receptor (PPAR)β/δ show promise. Remarkably, most of the antidiabetic effects of PPARβ/δ agonists involve AMP-activated protein kinase (AMPK) activation. This review summarizes the recent mechanistic insights into the antidiabetic effects of the PPARβ/δ-AMPK pathway, including the upregulation of glucose uptake, muscle remodeling, enhanced fatty acid oxidation, and autophagy, as well as the inhibition of endoplasmic reticulum stress and inflammation. A better understanding of the mechanisms underlying the effects resulting from the PPARβ/δ-AMPK pathway may provide the basis for the development of new therapies in the prevention and treatment of insulin resistance and type 2 diabetes mellitus.MDPI2022202220212022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/183848Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/ijms22168555International Journal of Molecular Sciences, 2021, vol. 22, num. 16, p. 8555https://doi.org/10.3390/ijms22168555cc-by (c) Aguilar-Recarte, David et al., 2021https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1838482026-05-29T05:05:01Z
dc.title.none.fl_str_mv The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
title The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
spellingShingle The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
Aguilar-Recarte, David
Trastorns del metabolisme dels lípids
Àcids grassos
Receptors nuclears (Bioquímica)
Glucosa
Lipid metabolism disorders
Fatty acids
Nuclear receptors (Biochemistry)
Glucose
title_short The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
title_full The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
title_fullStr The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
title_full_unstemmed The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
title_sort The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
dc.creator.none.fl_str_mv Aguilar-Recarte, David
Palomer Tarridas, Francesc Xavier
Wahli, Walter
Vázquez Carrera, Manuel
author Aguilar-Recarte, David
author_facet Aguilar-Recarte, David
Palomer Tarridas, Francesc Xavier
Wahli, Walter
Vázquez Carrera, Manuel
author_role author
author2 Palomer Tarridas, Francesc Xavier
Wahli, Walter
Vázquez Carrera, Manuel
author2_role author
author
author
dc.subject.none.fl_str_mv Trastorns del metabolisme dels lípids
Àcids grassos
Receptors nuclears (Bioquímica)
Glucosa
Lipid metabolism disorders
Fatty acids
Nuclear receptors (Biochemistry)
Glucose
topic Trastorns del metabolisme dels lípids
Àcids grassos
Receptors nuclears (Bioquímica)
Glucosa
Lipid metabolism disorders
Fatty acids
Nuclear receptors (Biochemistry)
Glucose
description The current treatment options for type 2 diabetes mellitus do not adequately control the disease in many patients. Consequently, there is a need for new drugs to prevent and treat type 2 diabetes mellitus. Among the new potential pharmacological strategies, activators of peroxisome proliferator-activated receptor (PPAR)β/δ show promise. Remarkably, most of the antidiabetic effects of PPARβ/δ agonists involve AMP-activated protein kinase (AMPK) activation. This review summarizes the recent mechanistic insights into the antidiabetic effects of the PPARβ/δ-AMPK pathway, including the upregulation of glucose uptake, muscle remodeling, enhanced fatty acid oxidation, and autophagy, as well as the inhibition of endoplasmic reticulum stress and inflammation. A better understanding of the mechanisms underlying the effects resulting from the PPARβ/δ-AMPK pathway may provide the basis for the development of new therapies in the prevention and treatment of insulin resistance and type 2 diabetes mellitus.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/183848
url https://hdl.handle.net/2445/183848
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/ijms22168555
International Journal of Molecular Sciences, 2021, vol. 22, num. 16, p. 8555
https://doi.org/10.3390/ijms22168555
dc.rights.none.fl_str_mv cc-by (c) Aguilar-Recarte, David et al., 2021
https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Aguilar-Recarte, David et al., 2021
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419467764662272
score 15.81155

Registos relacionados